clinical trial · NCT01546571
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
MelanomaPOL-103APOL-103A without API
brief summary
The purpose of this study is to determine how safe and how well POL-103A works in preventing the relapse of melanoma after patients who have undergone surgery.
started
May 1, 2012
primary completion
Apr 29, 2021
completion
Jun 30, 2021
last updated
Oct 24, 2025
official title
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol